ClinicalTrials.gg
RecruitingNCT07300189Updated Aug 21, 2026

A Study to Evaluate Single and Multiple Doses of TLC-1180 in Healthy Subjects

A Phase 1 interventional study of TLC-1180 Oral Solution and TLC-1180 Tablet in Healthy Participants, sponsored by OrsoBio, Inc. Recruiting at 1 site in New Zealand. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by OrsoBio, Inc · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.
Phase
Phase 1
Study type
Interventional
Enrollment
332
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TLC-1180 after single- and multiple-ascending doses in healthy subjects.

Read the detailed description

The primary objectives are to assess the safety, tolerability, and plasma PK of TLC-1180 in healthy subjects. The exploratory objective is to evaluate the PD of TLC-1180 in healthy subjects. This study is comprised of three parts: Part A (single-ascending dose), Part B (adaptive multiple-ascending dose), and Part C (adaptive single-ascending dose). Up to 72, 100, and 160 healthy subjects will be recruited in Parts A, B, and C, respectively.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

OrsoBio, Inc is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-smoking, healthy male or female subject between 18 and 55 years of age, inclusive
  • from 19 to 35 kg/m2, inclusive
  • Estimated ≥ 80 mL/min
  • Normal liver biochemistry tests
  • Screening laboratory evaluations (hematology, chemistry, and urinalysis) must fall within the normal range of the local laboratory's reference ranges unless the results have been determined by the investigator to have no clinical significance
  • Subject must have either a normal 12-lead (ECG) or one with abnormalities that are considered clinically insignificant by the investigator
  • Females of must have a negative pregnancy test at Screening and clinic admission
  • Male subjects and female subjects of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of
  • Must, in the opinion of the investigator, be in good health based upon medical history and physical examination, including vital signs

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating subjects
  • Subjects who have any serious or active medical or psychiatric illness (including depression) that, in the opinion of the investigator, would interfere with the subject's treatment, assessment, or compliance with the protocol
  • Subjects who have received any compound within 30 days or 5 half-lives, whichever is longer, prior to study drug dosing
  • Current alcohol abuse that is judged by the investigator to potentially interfere with the subject's compliance or safety
  • Current substance abuse that is judged by the investigator to potentially interfere with the subject's compliance or safety
  • A positive test result for (HIV-1) antibody, (HBV) surface antigen, or (HCV) antibody
  • Subjects who have taken any prescription medications or over-the-counter medications, including herbal products, within 28 days prior to start of study drug dosing, with the exception of vitamins, acetaminophen (paracetamol), ibuprofen, and/or hormonal medications
  • Subjects who have been treated with systemic , therapies, or chemotherapeutic agents within 3 months prior to Screening or expected to receive these agents during the study (e.g., corticosteroids, immunoglobulins, and other immune- or cytokine-based therapies)
  • Medical history of serious skin disease in the opinion of the investigator, such as but not limited to rash, food allergy, eczema, psoriasis, or urticaria
  • Medical history of drug sensitivity or drug allergy (such as anaphylaxis or hepatoxicity)
  • Presence or history of cardiovascular disease, including significant cardiovascular disease (including a history of myocardial infarction based on and/or clinical history), history of cardiac conduction abnormalities (including any history of ventricular tachycardia), congestive heart failure, cardiomyopathy with \< 40%, a family history of Long Syndrome, or unexplained death in an otherwise healthy individual between the ages of 1 and 30 years
  • Syncope, palpitations, or unexplained dizziness
  • Implanted defibrillator or pacemaker
  • Medical history of liver disease, including but not limited to alcoholic liver disease, disorders (e.g., primary biliary cholangitis, primary sclerosing cholangitis, autoimmune hepatitis), drug-induced hepatotoxicity, Wilson disease, iron overload, or alpha-1-antitrypsin deficiency)
  • History of rhabdomyolysis
  • Severe peptic ulcer disease, gastroesophageal reflux disease, or other gastric acid hypersecretory conditions
  • History of medical or surgical treatment that permanently alters intestinal absorption (e.g., gastric or intestinal surgery)
  • Subjects who have received vaccination for COVID-19 within 14 days of Admission

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
332 participants (estimated)

Study arms

  • Experimental
    Oral Solution

    Oral solution of TLC-1180

    Drug: TLC-1180 Oral Solution · Other: Placebo Oral Solution

  • Experimental
    Tablet

    Tablet formulation of TLC-1180

    Drug: TLC-1180 Tablet · Other: Placebo Tablet

Interventions

  • DrugTLC-1180 Oral Solution

    Oral solution of TLC-1180

  • DrugTLC-1180 Tablet

    Tablet formulation of TLC-1180

  • OtherPlacebo Oral Solution

    Placebo-to-match oral solution TLC-1180

  • OtherPlacebo Tablet

    Placebo-to-match tablet formulation of TLC-1180

06

What researchers measure

Primary outcomes

  1. Incidence of TLC-1180 treatment-emergent adverse events

    Adverse events (AEs) - severity of the AEs will be graded using the Common Terminology Criteria for AE (CTCAE) (v6.0). The relationship between AEs and the study drug will be indicated as related or not related.

    Time frame: Through study completion: Day 365 (Parts A, C); up to Day 421 (Part B) of the study

  2. PK of TLC-1180 AUC

    Area under the concentration-time curve

    Time frame: Through study completion: Day 365 (Parts A, C); up to Day 421 (Part B) of the study

  3. PK of TLC-1180 Cmax

    Maximum plasma concentration

    Time frame: Through study completion: Day 365 (Parts A, C); up to Day 421 (Part B) of the study

  4. PK of TLC-1180 tmax

    Time to reach Cmax

    Time frame: Through study completion: Day 365 (Parts A, C); up to Day 421 (Part B) of the study

  5. PK of TLC-1180 t1/2

    Half-life

    Time frame: Through study completion: Day 365 (Parts A, C); up to Day 421 (Part B) of the study

  6. PK of TLC-1180 CL/F

    Apparent clearance, calculated as dose/AUC0-inf

    Time frame: Through study completion: Day 365 (Parts A, C); up to Day 421 (Part B) of the study

07

Study locations

1 of 1 sites recruiting
  • OrsoBio Research Site
    Auckland, New Zealand
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Mar 2028, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2025
First posted
Dec 23, 2025
StartActual
Oct 20, 2025
Primary completionEst.
Mar 1, 2028
CompletionEst.
May 1, 2028
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07300189
Lead sponsor
OrsoBio, Inc
Responsible party
Sponsor
First posted
Dec 23, 2025
Start date
Oct 20, 2025
Primary completion
Mar 1, 2028 (estimated)
Completion
May 1, 2028 (estimated)
Last update
Aug 21, 2026

Study contacts

Ryan Huss, MD
Contact
Clinicaltrials_Inquires@orsobio.com
650-382-2225

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion